On February 16, 2018 Oncolys BioPharma ("Oncolys") reported that the board of the company resolved to enter
into an investment and share transfer agreement with Unleash Immuno Oncolytics, Inc. (Saint Louis, Missouri,
USA. CEO: Daniel Kazman hereinafter "Unleash"), a biotech venture specialized in development of novel
oncolytic adenovirus (Press release, Oncolys BioPharma, FEB 16, 2018, View Source [SID1234532349]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

1. Purpose of Investment

Unleash was established in 2015 by Dr. David Curiel, a top scientific leader with broad experience in oncolytic
virus, with the purpose to develop new adenovirus based cancer therapy. Its lead product, UIO-512, is an oncolytic
virus designed to target both malignant cells and tumor-associated stroma cells and currently under development
for refractory solid tumors. Unleash also has a novel pipeline, UIO-702, that is genetically modified virus with
camelid antibody incorporated to fiber so that it evades human immune responses. UIO-702 is a systemically
delivered oncolytic virus for neoplastic metastatic disease.
In addition to the purchase of convertible bonds issued by Unleash, Oncolys is to enter into a share transfer
agreement with Unleash to receive common shares of Precision Virologics Inc. (Saint Louis, Missouri, USA.
Chairman/CEO: Daniel Kazman hereinafter "Precision Virologics"), a Washington University biotech venture,
currently held by Unleash. Oncolys has been a shareholder of Precision Virologics since March 2017.
Oncolys strongly believes that a capital tie-up with Unleash and Precision Virologics, with their world-leading
gene-modification technology, can further reinforce its existing pipeline of cancer virotherapy led by its own
oncolytic adenovirus Telomelysin (OBP-301), and help to expand drug candidates portfolio in both cancer and
serious infectious diseases with no cure at present.
2. Details of the agreement
（1）Oncolys will be entitled to have a board seat within the board of directors of Unleash.
（2）Oncolys agrees to purchase $3,000,000 convertible bonds issued by Unleash with the expected voting rights
ratio of approximately 27%, when fully converted. Oncolys also agrees to purchase 294,118 ordinary shares of
Precision Virologics held by Unleash for $330,000, which will increase Oncolys’ voting rights ratio of
NB: this is a summary translation of the press release
original drafted in Japanese for the disclosure in
compliance with the TSE regulations. In case of any
discrepancy, the Japanese original shall prevail.
Precision from 14.3% to 23%, approximately.

（3）Number of shares purchased by Unleash and its ratio against shares outstanding: None
3. Overview of the companies

(1) Name Unleash Immuno Oncolytics, Inc.
(2) Address 4320 Forest Park Avenue, Saint Louis, MO 63108 USA
(3) Representative Daniel Katzman, CEO
(4) Type of Business Research and development of cancer immunotherapy based on
genetically modified adenovirus
(5) Establishment 26 August 2015
(6) Total Paid-In Capital Not applicable
(7) Major Shareholders Name/Ownership Attribution
Daniel Katzman Founder & CEO
Dr. David Curiel Founder & CSO
Washington University School of Medicine
Axia Ventures, LLC Venture Capital
Dr. Osvaldo Podhajcer Lead Scientific Advisor
Marina Scuseria Founder
(8) Relationship with Oncolys
Capital No
Personal No
Transactional No
Related Parties No
(9) Operating Performance and Financials in the previous 3 years （USD）
Fiscal Year Dec. 2015 Dec. 2016 Dec. 2017
Net Asset
N/A*
-133,548.19 -179,604.45
Total Asset 94,006.37 56,552.69
Sales － 61,500.00
Operating Profit -115,067.15 -32,055.31
Net Profit -130,597.84 -33,447.59
*No earnings report is available as Unleash was established in August 2015

(1) Name Precision Virologics Inc.
(2) Address 4320 Forest Park Ave
Saint Louis, Missouri 63108 USA
(3) Representative Daniel Katzman, CEO
(4) Type of Business Research and development of biologically targeted adenovirus based vaccines for
emerging infectious diseases
(5) Establishment 18 February 2012 as Precision Virologics, LLC.
Converted to Precision Virologics, Inc. in August 2016.
(6) Total Paid-In Capital Not applicable
(7) Major Shareholders Name/Ownership Attribution
Dr. David Curiel Founder & CSO
Washington University School of Medicine
Daniel Katzman CEO
Oncolys BioPharma Listed company
Unleash Immuno Oncolytics Private company
(8)Relationship with Oncolys Capital Ordinary shares: 14%
Personal Board member: 1
Transactional First refusal right in Asian countries with relation to all projects
developed by Precision Virologics
Related Parties No
(9) Operating Performance and Financials in the previous 3 years
Fiscal Year Dec. 2015 Dec. 2016 Dec. 2017
Net Asset
No earnings report filed for these years as the
company was converted from Precision Virologics,
LLC. to Precision Virologics Inc. in August 2016.
409,512.75
Total Asset 409,512.75
Sales –
Net Profit -90,497.27
4. Schedule
(1) Board Resolution 16 February 2018
(2) Execution of Agreement February 2018（provisional）
(3) Execution of Investment February 2018（provisional）
5. Future Outlook
As neither Unleash nor Precision Virologics falls under the category of equity method affiliates for Oncolys, the
announcement above will not significantly affect Oncolys’ earnings for the fiscal year ending 31 December 2018.